Ethris GmbHThe COVID 19 pandemic demonstrated that Europe can move fast, take risk, and deliver world class vaccines when political will, science and capital are aligned. Treating vaccines as strategic assets, backed by sustained political and financial support, will be key to maintaining Europe’s long-term investment in public health and innovation.
Tag Archive for: Europe
Featuring 100 exhibitors, keynote and podium speakers, behind-the-scenes access to a leading biotech campus, and a rich networking program, SLAS Europe 2026 is designed for professionals at every stage of their careers.
Sofinnova PartnersCapital is tight and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures.
Die Hoffotografen GmbHSolid tumours pose major obstacles for cell therapies, but German-American biotech T-knife is tackling them head-on. CEO Tom Soloway and CTO Elisa Kieback share how their “supercharged” TCR-Ts are engineered to overcome these challenges.
Boehmert & BoehmertNew developments under the current U.S. administration may be a challenge for the pharma/biotech industry: the Inflation Reduction Act, Orange Book Challenges, Most Favored Nation Policy, and the new Trump-Lutnick Patent Tax. And it will likely affect European pharma and biotech.
Jeremy Levin, Ovid TherapeuticsOn May 12, 2025, President Donald Trump signed an executive order aiming to drastically reduce U.S. prescription drug prices by aligning them with the lowest prices paid in other developed nations—a policy known as the “Most Favored Nation” (MFN) approach. While the initiative seeks to alleviate the financial burden on American patients, it has sparked intense debate over its potential ramifications on global pharmaceutical trade, investment patterns, and the United States’ leadership in biomedical innovation.
EvonikThe U.S. administration of President Donald Trump has revoked Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” originally issued on September 12, 2022. This decision will have far-reaching consequences for the U.S. biotech industry.
YEBNThe Young European Biotech Network (YEBN) is preparing for a busy semester, with a variety of events and initiatives planned through the end of 2024. From launching a new community platform to hosting key events, YEBN aims to support innovation, facilitate collaboration, and address the evolving needs of the biotech community.
Expanding networks: Comprised of passionate individuals committed to driving positive change, YEBN board brings a wealth of diverse experiences and expertise to guide the association towards new heights of success.
Boehmert & BoehmertIn times of the pandemic it was called to ban patents that are related to Covid-19 vaccines, medicaments, and diagnostics and the European Parliament was in favour of it. Now there is a call from the European Parliament to ban all patents on new genomics techniques (NTG) and plants. Quo vadis?